{"entity":{"id":"georgetown-lombardi","kind":"institution","name":"Georgetown Lombardi Comprehensive Cancer Center","aka":[],"tldr":"The only NCI comprehensive cancer centre in Washington, DC, known for breast cancer research including leadership of the CLEOPATRA pertuzumab trial.","summary":"NCI-designated since 1974, Georgetown Lombardi is Washington's only comprehensive cancer centre and since 2019 has formed a consortium with Hackensack Meridian's John Theurer Cancer Center in New Jersey. Breast cancer has been its signature: Marc Lippman and Robert Clarke built the hormone-receptor and endocrine-resistance programme, and Sandra Swain led CLEOPATRA, which established pertuzumab plus trastuzumab and docetaxel as first-line therapy for HER2-positive metastatic breast cancer. Louis Weiner's antibody immunotherapy laboratory and a cancer-prevention and population-science programme focused on the DC region round out the portfolio. Care is delivered at MedStar Georgetown University Hospital.","asOf":"2026-09-09","links":[{"label":"Georgetown Lombardi","url":"https://lombardi.georgetown.edu"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":["monoclonal-antibody","endocrine-therapy","proton-therapy","proton-therapy-systems","cyberknife","radiosurgery-srs"],"targets":["her2","estrogen-receptor"],"drugs":["pertuzumab","trastuzumab","docetaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cleopatra"],"people":["sandra-swain"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Washington, DC","country":"US","lat":38.911,"lng":-77.075,"institutionType":"cancer-center","website":"https://lombardi.georgetown.edu","nci":"comprehensive","university":"Georgetown University","programs":["Breast cancer (CLEOPATRA)","Antibody immunotherapy","Consortium with John Theurer Cancer Center"]},"route":"/institutions/georgetown-lombardi/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"cyberknife","kind":"technology","name":"CyberKnife robotic radiosurgery","route":"/technologies/cyberknife/"},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/"},{"id":"proton-therapy-systems","kind":"technology","name":"Proton therapy machines: cyclotrons, synchrotrons and single-room systems","route":"/technologies/proton-therapy-systems/"},{"id":"radiosurgery-srs","kind":"technology","name":"Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)","route":"/technologies/radiosurgery-srs/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"trial":[{"id":"cleopatra","kind":"trial","name":"CLEOPATRA","route":"/trials/cleopatra/"}],"person":[{"id":"michael-atkins","kind":"person","name":"Michael B. Atkins","route":"/people/michael-atkins/"},{"id":"sandra-swain","kind":"person","name":"Sandra M. Swain","route":"/people/sandra-swain/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}]}}